Telo Genomics raising capital for multiple myeloma solution

• Telo Genomics is announcing a $2 million private placement to further its multiple myeloma initiatives
• The funds will go toward launching Telo-MM, the company’s lead product to treat multiple myeloma, as well as advancing related research with the Mayo Clinic
• The capital will also advance the company’s pursuit of ISO 15189 certification and certified Clinical Laboratory Improvement Amendments accreditation
• Telo Genomics is a biotech company pioneering a comprehensive DNA-based platform with powerful applications and prognostic solutions
• Telo Genomics (TSXV:TELO) is unchanged trading at $0.30 per share

Telo Genomics is announcing a $2 million private placement to further its multiple myeloma initiatives.

Telo will use the proceeds to fund:

• The commercial launch of Telo-MM, its lead product, which is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer
• Its ongoing collaborative studies with the Mayo Clinic in multiple myeloma
• ISO 15189 certification and certified Clinical Laboratory Improvement Amendments accreditation
• General working capital purposes

The non-brokered private placement will offer units at $0.25 each.

Each unit consists of one common share and one-half of one non-transferable common share purchase warrant.

Each warrant will entitle the holder to acquire one common share for $0.40 for 24 months from the date of issuance.

All securities issued will be subject to a four-month hold period from the date of issuance.

Telo Genomics is a biotech company pioneering a comprehensive DNA-based platform with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology (multiple myeloma) and neurological diseases (Alzheimer’s Disease). 

Telo Genomics (TSXV:TELO) is unchanged trading at $0.30 per share.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.